Regulation of TNF-α with a focus on rheumatoid arthritis

Immunology and Cell Biology

Volumn 91, Issue 6, 2013, Pages 393-401

  Moelants, Eva A V ^a   Mortier, Anneleen ^a   Van Damme, Jo ^a   Proost, Paul ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

autoantibodies; cytokine; post translational modification; rheumatoid arthritis; TNF

Indexed keywords

ADALIMUMAB; CANAKINUMAB; CERTOLIZUMAB PEGOL; DENOSUMAB; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

CYTOKINE RELEASE; GENETIC REGULATION; GENETIC TRANSCRIPTION; HUMAN; OSTEOLYSIS; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TRANSLATION INITIATION;

ANIMALS; ARTHRITIS, RHEUMATOID; GENE EXPRESSION REGULATION; HUMANS; IMMUNOTHERAPY; INFLAMMATION MEDIATORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879838047     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2013.15     Document Type: Review

References (133)

1. Schett G, Gravallese E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol 2012; 8: 656-664.
2. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008; 118: 3537-3545.
3. Edwards CJ. Immunological therapies for rheumatoid arthritis. Br Med Bull 2005; 73-74: 71-82. (Pubitemid 43020359)
4. Thalayasingam N, Isaacs JD. Anti-TNF therapy. Best Pract Res Clin Rheumatol 2011; 25: 549-567.
5. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358: 903-911. (Pubitemid 32900579)
6. Lundstrom E, Kallberg H, Alfredsson L, Klareskog L, Padyukov L. Gene-environment interaction between the DRB1 shared epitope and smoking in the risk of anticitrullinated protein antibody-positive rheumatoid arthritis: all alleles are important. Arthritis Rheum 2009; 60: 1597-1603.
7. Kallberg H, Padyukov L, Plenge RM, Ronnelid J, Gregersen PK, van der Helm-van Mil AH et al. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 2007; 80: 867-875. (Pubitemid 46668455)
8. Goldring SR, Gravallese EM. Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol 2000; 12: 195-199. (Pubitemid 30238387)
9. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000; 43: 250-258. (Pubitemid 30395732)
10. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007; 7: 429-442. (Pubitemid 46834849)
11. Seitz M, Loetscher P, Fey MF, Tobler A. Constitutive mRNA and protein production of macrophage colony-stimulating factor but not of other cytokines by synovial fibroblasts from rheumatoid arthritis and osteoarthritis patients. Br J Rheumatol 1994; 33: 613-619. (Pubitemid 24222111)
12. Clinton SK, Underwood R, Hayes L, Sherman ML, Kufe DW, Libby P. Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. Am J Pathol 1992; 140: 301-316.
13. Nakano K, Okada Y, Saito K, Tanikawa R, Sawamukai N, Sasaguri Y et al. Rheumatoid synovial endothelial cells produce macrophage colony-stimulating factor leading to osteoclastogenesis in rheumatoid arthritis. Rheumatology (Oxford) 2007; 46: 597-603. (Pubitemid 46523302)
14. Crotti TN, Smith MD, Weedon H, Ahern MJ, Findlay DM, Kraan M et al. Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis 2002; 61: 1047-1054. (Pubitemid 35397349)
15. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-319. (Pubitemid 27199902)
16. Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen JS et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2000; 2: 236-243. (Pubitemid 32223739)
17. Harre U, Georgess D, Bang H, Bozec A, Axmann R, Ossipova E et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 2012; 122: 1791-1802.
18. Braun T, Zwerina J. Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis. Arthritis Res Ther 2011; 13: 235.
19. Zhang YH, Heulsmann A, Tondravi MM, Mukherjee A, Abu-Amer Y. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem 2001; 276: 563-568. (Pubitemid 32050352)
20. Li P, Schwarz EM, O'Keefe RJ, Ma L, Boyce BF, Xing L. RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis. J Bone Miner Res 2004; 19: 207-213. (Pubitemid 38116734)
21. Gilbert L, He X, Farmer P, Boden S, Kozlowski M, Rubin J et al. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology 2000; 141: 3956-3964.
22. Koch AE. Chemokines and their receptors in rheumatoid arthritis: future targets? Arthritis Rheum 2005; 52: 710-721. (Pubitemid 40365092)
23. Mohan AK, Cote TR, Siegel JN, Braun MM. Infectious complications of biologic treatments of rheumatoid arthritis. Curr Opin Rheumatol 2003; 15: 179-184. (Pubitemid 36532595)
24. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxininduced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72: 3666-3670.
25. Medzhitov R, Horng T. Transcriptional control of the inflammatory response. Nat Rev Immunol 2009; 9: 692-703.
26. Shebzukhov YV, Kuprash DV. Transcriptional regulation of TNF/LT locus in immune cells. Mol Biol 2011; 45: 56-67.
27. Murr R. Interplay between different epigenetic modifications and mechanisms. Adv Genet 2010; 70: 101-141.
28. Bates PW, Miyamoto S. Expanded nuclear roles for IkappaBs. Sci STKE 2004; 2004: e48.
29. Espel E. The role of the AU-rich elements of mRNAs in controlling translation. Semin Cell Dev Biol 2005; 16: 59-67. (Pubitemid 40136538)
30. Bak RO, Mikkelsen JG. Regulation of cytokines by small RNAs during skin inflammation. J Biomed Sci 2010; 17: 53.
31. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999; 10: 387-398. (Pubitemid 29165293)
32. Carballo E, Lai WS, Blackshear PJ. Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science 1998; 281: 1001-1005. (Pubitemid 28399252)
33. Taylor GA, Carballo E, Lee DM, Lai WS, Thompson MJ, Patel DD et al. A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity 1996; 4: 445-454. (Pubitemid 26354654)
34. Asirvatham AJ, Gregorie CJ, Hu Z, Magner WJ, Tomasi TB. MicroRNA targets in immune genes and the Dicer/Argonaute and ARE machinery components. Mol Immunol 2008; 45: 1995-2006. (Pubitemid 351226272)
35. Tili E, Michaille JJ, Cimino A, Costinean S, Dumitru CD, Adair B et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol 2007; 179: 5082-5089.
36. Huang HC, Yu HR, Huang LT, Huang HC, Chen RF, Lin IC et al. miRNA-125b regulates TNF-alpha production in CD14+ neonatal monocytes via post-transcriptional regulation. J Leukoc Biol 2012; 92: 171-182.
37. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007; 318: 1931-1934.
38. Jing Q, Huang S, Guth S, Zarubin T, Motoyama A, Chen J et al. Involvement of microRNA in AU-rich element-mediated mRNA instability. Cell 2005; 120: 623-634. (Pubitemid 40343075)
39. Aggarwal BB. Signaling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003; 3: 745-756. (Pubitemid 41070815)
40. Callard R, Gearing A. The Cytokine FactsBook. Academic Press, London, 1994.
41. Winzen R, Wallach D, Kemper O, Resch K, Holtmann H. Selective up-regulation of the 75-kDa tumor necrosis factor (TNF) receptor and its mRNA by TNF and IL-1. J Immunol 1993; 150: 4346-4353. (Pubitemid 23133711)
42. Ding AH, Sanchez E, Srimal S, Nathan CF. Macrophages rapidly internalize their tumor necrosis factor receptors in response to bacterial lipopolysaccharide. J Biol Chem 1989; 264: 3924-3929. (Pubitemid 19072279)
43. Kemper O, Wallach D. Cloning and partial characterization of the promoter for the human p55 tumor necrosis factor (TNF) receptor. Gene 1993; 134: 209-216.
44. Santee SM, Owen-Schaub LB. Human tumor necrosis factor receptor p75/80 (CD120b) gene structure and promoter characterization. J Biol Chem 1996; 271: 21151-21159. (Pubitemid 26292967)
45. Engelmann H, Aderka D, Rubinstein M, Rotman D, Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989; 264: 11974-11980. (Pubitemid 19185371)
46. Hino T, Nakamura H, Abe S, Saito H, Inage M, Terashita K et al. Hydrogen peroxide enhances shedding of type I soluble tumor necrosis factor receptor from pulmonary epithelial cells. Am J Respir Cell Mol Biol 1999; 20: 122-128. (Pubitemid 129504850)
47. Okuyama M, Yamaguchi S, Yamaoka M, Nitobe J, Fujii S, Yoshimura T et al. Nitric oxide enhances expression and shedding of tumor necrosis factor receptor I (p55) in endothelial cells. Arterioscler Thromb Vasc Biol 2000; 20: 1506-1511. (Pubitemid 30353881)
48. Brennan FM, Gibbons DL, Mitchell T, Cope AP, Maini RN, Feldmann M. Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints. Eur J Immunol 1992; 22: 1907-1912.
49. Faustman D, Davis M. TNF receptor 2 pathway: drug target for autoimmune diseases. Nat Rev Drug Discov 2010; 9: 482-493.
50. Cope AP, Aderka D, Doherty M, Engelmann H, Gibbons D, Jones AC et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992; 35: 1160-1169.
51. Barton A, John S, Ollier WE, Silman A, Worthington J. Association between rheumatoid arthritis and polymorphism of tumor necrosis factor receptor II, but not tumor necrosis factor receptor I, in Caucasians. Arthritis Rheum 2001; 44: 61-65. (Pubitemid 32113119)
52. Standiford TJ, Strieter RM, Lukacs NW, Kunkel SL. Neutralization of IL-10 increases lethality in endotoxemia. Cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. J Immunol 1995; 155: 2222-2229.
53. Bemelmans MH, van Tits LJ, Buurman WA. Tumor necrosis factor: function, release and clearance. Crit Rev Immunol 1996; 16: 1-11. (Pubitemid 26239999)
54. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385: 729-733. (Pubitemid 27098094)
55. Ruuls SR, Hoek RM, Ngo VN, McNeil T, Lucian LA, Janatpour MJ et al. Membranebound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity 2001; 15: 533-543. (Pubitemid 33016439)
56. Van Lint P, Libert C. Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J Leukoc Biol 2007; 82: 1375-1381. (Pubitemid 350276947)
57. Larché MJ, Sacre SM, Foxwell BM. Pathogenic role of TNF [alpha] in rheumatoid arthritis. Drug Discovery Today: Disease Mechanisms 2005; 2: 367-375.
58. Schiff MH. Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis. Ann Rheum Dis 2000; 59 (Suppl 1), i103-i108.
59. Foulquier C, Sebbag M, Clavel C, Chapuy-Regaud S, Al Badine R, Mechin MC et al. Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum 2007; 56: 3541-3553. (Pubitemid 350100687)
60. Chang X, Yamada R, Suzuki A, Sawada T, Yoshino S, Tokuhiro S et al. Localization of peptidylarginine deiminase 4 (PADI4) and citrullinated protein in synovial tissue of rheumatoid arthritis. Rheumatology (Oxford) 2005; 44: 40-50. (Pubitemid 40124330)
61. Suzuki A, Yamada R, Chang X, Tokuhiro S, Sawada T, Suzuki M et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 2003; 34: 395-402. (Pubitemid 36935332)
62. Moelants EAV, Mortier A, Grauwen K, Ronsse I, Van Damme J, Proost P. Citrullination of TNF-alpha by peptidylarginine deiminases reduces its capacity to stimulate the production of inflammatory chemokines. Cytokine 2012; 61: 161-167.
63. Mukai Y, Shibata H, Nakamura T, Yoshioka Y, Abe Y, Nomura T et al. Structurefunction relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant. J Mol Biol 2009; 385: 1221-1229.
64. Mukai Y, Nakamura T, Yoshioka Y, Tsunoda S, Kamada H, Nakagawa S et al. Crystallization and preliminary X-ray analysis of the tumour necrosis factor alphatumour necrosis factor receptor type 2 complex. Acta Crystallogr Sect F Struct Biol Cryst Commun 2009; 65: 295-298.
65. Mukai Y, Nakamura T, Yoshikawa M, Yoshioka Y, Tsunoda S, Nakagawa S et al. Solution of the structure of the TNF-TNFR2 complex. Sci Signal 2010; 3: ra83.
66. Bradley Jr. TNF-mediated inflammatory disease. J Pathol 2008; 214: 149-160. (Pubitemid 351160153)
67. Naude PJ, den Boer JA, Luiten PG, Eisel UL. Tumor necrosis factor receptor cross-talk. FEBS J 2011; 278: 888-898.
68. Pimentel-Muinos FX, Seed B. Regulated commitment of TNF receptor signaling: a molecular switch for death or activation. Immunity 1999; 11: 783-793. (Pubitemid 30030717)
69. Ledgerwood EC, Pober JS, Bradley Jr. Recent advances in the molecular basis of TNF signal transduction. Lab Invest 1999; 79: 1041-1050. (Pubitemid 29444534)
70. Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995; 83: 793-802.
71. Abu-Amer Y, Erdmann J, Alexopoulou L, Kollias G, Ross FP, Teitelbaum SL. Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis. J Biol Chem 2000; 275: 27307-27310.
72. Jiang Y, Woronicz JD, Liu W, Goeddel DV. Prevention of constitutive TNF receptor 1 signaling by silencer of death domains. Science 1999; 283: 543-546.
73. Kanazawa K, Kudo A. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis. J Bone Miner Res 2005; 20: 840-847.
74. Hsu H, Huang J, Shu HB, Baichwal V, Goeddel DV. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 1996; 4: 387-396. (Pubitemid 26174054)
75. Hsu H, Shu HB, Pan MG, TRADD-TRAF2 GoeddelDV. and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 1996; 84: 299-308. (Pubitemid 26042835)
76. Yang J, Lin Y, Guo Z, Cheng J, Huang J, Deng L et al. The essential role of MEKK3 in TNF-induced NF-kappaB activation. Nat Immunol 2001; 2: 620-624. (Pubitemid 32677629)
77. Israel A. The IKK complex: an integrator of all signals that activate NF-kappaB? Trends Cell Biol 2000; 10: 129-133. (Pubitemid 30171300)
78. Akira S, Kishimoto T. IL-6 and NF-IL6 in acute-phase response and viral infection. Immunol Rev 1992; 127: 25-50.
79. Devin A, Lin Y, Yamaoka S, Li Z, Karin M, Liu Z. The alpha and beta subunits of IkappaB kinase (IKK) mediate TRAF2-dependent IKK recruitment to tumor necrosis factor (TNF) receptor 1 in response to TNF. Mol Cell Biol 2001; 21: 3986-3994. (Pubitemid 32476460)
80. Deacon K, Blank JL. MEK kinase 3 directly activates MKK6 and MKK7, specific activators of the p38 and c-Jun NH2-terminal kinases. J Biol Chem 1999; 274: 16604-16610.
81. Karin M, Gallagher E. From JNK to pay dirt: jun kinases, their biochemistry, physiology and clinical importance. IUBMB Life 2005; 57: 283-295. (Pubitemid 40904256)
82. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281: 1305-1308. (Pubitemid 28406815)
83. Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J. NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol 2001; 21: 5299-5305. (Pubitemid 32702435)
84. Rothe M, Pan MG, Henzel WJ, Ayres TM, Goeddel DV. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 1995; 83: 1243-1252. (Pubitemid 26007814)
85. Rothe M, Wong SC, Henzel WJ, Goeddel DV. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 1994; 78: 681-692. (Pubitemid 24268590)
86. Cabal-Hierro L, Lazo PS. Signal transduction by tumor necrosis factor receptors. Cell Signal 2012; 24: 1297-1305.
87. Malinin NL, Boldin MP, Kovalenko AV, Wallach D. MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature 1997; 385: 540-544. (Pubitemid 27074673)
88. Li X, Yang Y, JD Ashwell. TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature 2002; 416: 345-347.
89. Zhang R, Xu Y, Ekman N, Wu Z, Wu J, Alitalo K et al. Etk/Bmx transactivates vascular endothelial growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factor-induced angiogenic pathway. J Biol Chem 2003; 278: 51267-51276. (Pubitemid 38020364)
90. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14: 397-440. (Pubitemid 26130190)
91. Pierer M, Rethage J, Seibl R, Lauener R, Brentano F, Wagner U et al. Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by Toll-like receptor 2 ligands. J Immunol 2004; 172: 1256-1265. (Pubitemid 38113789)
92. MacNaul KL, Hutchinson NI, Parsons JN, Bayne EK, Tocci MJ. Analysis of IL-1 and TNF-alpha gene expression in human rheumatoid synoviocytes and normal monocytes by in situ hybridization. J Immunol 1990; 145: 4154-4166.
93. Millet I, Ruddle NH. Differential regulation of lymphotoxin (LT), lymphotoxin-beta (LT-beta), and TNF-alpha in murine T cell clones activated through the TCR. J Immunol 1994; 152: 4336-4346. (Pubitemid 24134391)
94. Grivennikov SI, Tumanov AV, Liepinsh DJ, Kruglov AA, Marakusha BI, Shakhov AN et al. Distinct and nonredundant in vivo functions of TNF produced by T cells and macrophages/neutrophils: protective and deleterious effects. Immunity 2005; 22: 93-104. (Pubitemid 40143454)
95. Ahern DJ, Brennan FM. The role of natural killer cells in the pathogenesis of rheumatoid arthritis: major contributors or essential homeostatic modulators? Immunol Lett 2011; 136: 115-121.
96. Modrowski D, Godet D, Marie PJ. Involvement of interleukin 1 and tumour necrosis factor alpha as endogenous growth factors in human osteoblastic cells. Cytokine 1995; 7: 720-726.
97. McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat Med 1997; 3: 189-195. (Pubitemid 27064704)
98. Joosten LA, Koenders MI, Smeets RL, Heuvelmans-Jacobs M, Helsen MM, Takeda K et al. Toll-like receptor 2 pathway drives streptococcal cell wall-induced joint inflammation: critical role of myeloid differentiation factor 88. J Immunol 2003; 171: 6145-6153. (Pubitemid 37467237)
99. Edwards SW, Hallett MB. Seeing the wood for the trees: the forgotten role of neutrophils in rheumatoid arthritis. Immunol Today 1997; 18: 320-324. (Pubitemid 27314467)
100. Dalbeth N, Gundle R, Davies RJ, Lee YC, McMichael AJ, Callan MF et al. CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation. J Immunol 2004; 173: 6418-6426. (Pubitemid 39487802)
101. Palmblad K, Erlandsson-Harris H, Tracey KJ, Andersson U. Dynamics of early synovial cytokine expression in rodent collagen-induced arthritis: a therapeutic study using a macrophage-deactivating compound. Am J Pathol 2001; 158: 491-500. (Pubitemid 32158610)
102. Marinova-Mutafchieva L, Williams RO, Mason LJ, Mauri C, Feldmann M, Maini RN. Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis (CIA). Clin Exp Immunol 1997; 107: 507-512. (Pubitemid 27102139)
103. Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol 1993; 11: 767-804. (Pubitemid 23115023)
104. Brennan FM, Zachariae CO, Chantry D, Larsen CG, Turner M, Maini RN et al. Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells. Eur J Immunol 1990; 20: 2141-2144. (Pubitemid 20355642)
105. Koch AE, Kunkel SL, Burrows JC, Evanoff HL, Haines GK, Pope RM et al. Synovial tissue macrophage as a source of the chemotactic cytokine IL-8. J Immunol 1991; 147: 2187-2195.
106. Strieter RM, Kasahara K, Allen RM, Standiford TJ, Rolfe MW, Becker FS et al. Cytokine-induced neutrophil-derived interleukin-8. Am J Pathol 1992; 141: 397-407.
107. Van Damme J, Decock B, Conings R, Lenaerts JP, Opdenakker G, Billiau A. The chemotactic activity for granulocytes produced by virally infected fibroblasts is identical to monocyte-derived interleukin 8. Eur J Immunol 1989; 19: 1189-1194. (Pubitemid 19196894)
108. McCain RW, Holden EP, Blackwell TR, Christman JW. Leukotriene B4 stimulates human polymorphonuclear leukocytes to synthesize and release interleukin-8 in vitro. Am J Respir Cell Mol Biol 1994; 10: 651-657.
109. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005; 115: 282-290. (Pubitemid 40385470)
110. Munker R, Gasson J, Ogawa M, Koeffler HP. Recombinant human TNF induces production of granulocyte-monocyte colony-stimulating factor. Nature 1986; 323: 79-82. (Pubitemid 16012354)
111. Van Damme J, Cayphas S, Van Snick J, Conings R, Put W, Lenaerts JP et al. Purification and characterization of human fibroblast-derived hybridoma growth factor identical to T-cell-derived B-cell stimulatory factor-2 (interleukin-6). Eur J Biochem 1987; 168: 543-550. (Pubitemid 17159430)
112. Sarkar S, Fox DA. Dendritic cells in rheumatoid arthritis. Front Biosci 2005; 10: 656-665.
113. Zou GM, Tam YK. Cytokines in the generation and maturation of dendritic cells: recent advances. Eur Cytokine Netw 2002; 13: 186-199. (Pubitemid 34747919)
114. Paleolog EM. Angiogenesis in rheumatoid arthritis. Arthritis Res 2002; 4 (Suppl 3), S81-S90.
115. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002; 3: 889-901. (Pubitemid 35460788)
116. Shinohara M, Koga T, Okamoto K, Sakaguchi S, Arai K, Yasuda H et al. Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. Cell 2008; 132: 794-806. (Pubitemid 351312796)
117. Hwang SY, Putney JW Jr. Calcium signaling in osteoclasts. Biochim Biophys Acta 2011; 1813: 979-983.
118. Sato K, Suematsu A, Nakashima T, Takemoto-Kimura S, Aoki K, Morishita Y et al. Regulation of osteoclast differentiation and function by the CaMK-CREB pathway. Nat Med 2006; 12: 1410-1416. (Pubitemid 44924500)
119. Nakao S, Ogtata Y, Shimizu E, Yamazaki M, Furuyama S, Sugiya H. Tumor necrosis factor alpha (TNF-alpha)-induced prostaglandin E2 release is mediated by the activation of cyclooxygenase-2 (COX-2) transcription via NFkappaB in human gingival fibroblasts. Mol Cell Biochem 2002; 238: 11-18. (Pubitemid 35023524)
120. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007; 13: 156-163.
121. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000; 191: 275-286.
122. Abu-Amer Y, Ross FP, Edwards J, Teitelbaum SL. Lipopolysaccharide- stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor. J Clin Invest 1997; 100: 1557-1565. (Pubitemid 27425783)
123. Kanazawa K, Azuma Y, Nakano H, Kudo A. TRAF5 functions in both RANKL- and TNFalpha-induced osteoclastogenesis. J Bone Miner Res 2003; 18: 443-450. (Pubitemid 36241060)
124. Herold M. Rheumatoid arthritis. In: Shoenfeld Y and Meroni PL (eds). The General Practice Guide to Autoimmune Disease. Pabst Science Publisher, Lengerich, 2012: 63-71.
125. Verweij CL. Predicting the future of anti-tumor necrosis factor therapy. Arthritis Res Ther 2009; 11: 115.
126. Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000; 43: 1001-1009. (Pubitemid 30368176)
127. Alten R, Gomez-Reino J, Durez P, Beaulieu A, Sebba A, Krammer G et al. Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study. BMC Musculoskelet Disord 2011; 12: 153.
128. Hamdy NA. Denosumab: RANKL inhibition in the management of bone loss. Drugs Today (Barc) 2008; 44: 7-21. (Pubitemid 351397410)
129. Haringman JJ, Kraan MC, Smeets TJ, Zwinderman KH, Tak PP. Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62: 715-721. (Pubitemid 36886404)
130. Liu J, Merritt Jr. CC chemokine receptor small molecule antagonists in the treatment of rheumatoid arthritis and other diseases: a current view. Curr Top Med Chem 2010; 10: 1250-1267.
131. Suzuki N, Nakajima A, Yoshino S, Matsushima K, Yagita H, Okumura K. Selective accumulation of CCR5+ T lymphocytes into inflamed joints of rheumatoid arthritis. Int Immunol 1999; 11: 553-559. (Pubitemid 29179003)
132. Zapico I, Coto E, Rodriguez A, Alvarez C, Torre JC, Alvarez V. CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis. Genes Immun 2000; 1: 288-289.
133. van Kuijk AW, Vergunst CE, Gerlag DM, Bresnihan B, Gomez-Reino JJ, Rouzier R et al. CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis 2010; 69: 2013-2016.